Propanc Biopharma, an Australian biotech company, has announced a $100 million funding round from Hexstone Capital, a family office specializing in digital assets. The financing, structured as a private placement of convertible preferred shares, begins with an initial $1 million investment, with up to $99 million in additional funding expected over the next year. The funds will be allocated to expanding Propanc's digital asset portfolio and advancing the development of its cancer therapy, PRP. The company aims to commence first-in-human trials by 2026. While Propanc has not specified which digital assets it intends to acquire, Hexstone Capital's focus includes Bitcoin, Ethereum, Solana, and Dogecoin.